2. Epigenetics Stem Cell/Wnt MAPK/ERK Pathway
  3. Epigenetic Reader Domain ERK
  4. Molibresib besylate

Molibresib besylate  (Synonyms: GSK 525762C; I-BET 762 besylate)

製品番号: HY-13032B 純度: 97.04%
COA 取扱説明書 Technical Support

Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1895049-20-3

容量 価格（税別） 在庫状況 数量
>無料サンプル (0.1 - 0.2 mg)   今すぐ申し込む  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 136 在庫あり
Solution
10 mM * 1 mL in DMSO USD 136 在庫あり
Solid
5 mg $106 在庫あり
10 mg $156 在庫あり
25 mg $285 在庫あり
50 mg $456 在庫あり
100 mg $750 在庫あり
200 mg $1200 在庫あり
500 mg   お問い合わせ  
1 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 21 publication(s) in Google Scholar

Other Forms of Molibresib besylate:

Molibresib besylate 関連抗体

Top Publications Citing Use of Products

    Molibresib besylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 2;15(1):5570.  [Abstract]

    HL-60 cells were treated daily with 25% GI50 concentrations of CM-444, CM-1758, Molibresib, and JQ1, or CM-444 or CM-1758 in combination with Molibresib or JQ1, for 48 hours. The cell differentiation experiment was performed by detecting CD11b by flow cytometry.

    Molibresib besylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 2;15(1):5570.  [Abstract]

    ML-2 cells were treated daily with 25% GI50 concentrations of CM-444, CM-1758, Molibresib, and JQ1, or CM-444 or CM-1758 in combination with Molibresib or JQ1, for 48 hours. The cell differentiation experiment was performed by detecting CD11b by flow cytometry.

    Molibresib besylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 2;15(1):5570.  [Abstract]

    q-PCR results of GATA2, PU.1, SCL and CEBPA in HL-60 cells after daily treatment with 25% GI50 concentrations of CM-444, CM-1758, Molibresib, JQ1, and CM-444 or CM-1758 in combination with Molibresib or JQ1 for 48 hours.

    Molibresib besylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 2;15(1):5570.  [Abstract]

    q-PCR results of GATA2, PU.1, SCL and CEBPA in ML-2 cells after daily treatment with 25% GI50 concentrations of CM-444, CM-1758, Molibresib, JQ1, and CM-444 or CM-1758 in combination with Molibresib or JQ1 for 48 hours.

    Molibresib besylate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 Feb 19;7(8):eabe4038.  [Abstract]

    Comparison of expression levels of molibresib targets BRD2, BRD3 and BRD4 between leukemic and nonleukemic cells of AML1.

    Molibresib besylate purchased from MedChemExpress. Usage Cited in: Nat Med. 2017 Sep;23(9):1055-1062.  [Abstract]

    Western blot of WCL of C4-2 cells treated with vehicle (DMSO) or different doses of JQ1 or i-BET for 24 h. Actin is used as a loading control.

    Molibresib besylate purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Jun 21;7(25):38319-38332.  [Abstract]

    iBET762 partially disrupts the interaction between full-length ERG and BRD4 (A), and between T1-E4 ERG and BRD4 (B).

    Epigenetic Reader Domain アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    Brd BRPF1 BRPF2 BRPF3 BRD2 BRD3 BRD4 BRDT CECR2 BD1 BD2 BRD7 BRD9 BET BAZ

    ERK アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    ERK ERK1 ERK2 ERK5 ERK8

    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Molibresib besylate (GSK 525762C; I-BET 762 besylate) is an orally active pan-BET inhibitor that targets and binds to BRD2, BRD3, BRD4 and BRDT. By competitively occupying acetylated lysine binding sites, Molibresib besylate disrupts the interaction between BET proteins and chromatin, thereby effectively inhibiting MYC expression and target gene transcription. Molibresib besylate exhibits broad antiproliferative activity, which not only inhibits cancer cell growth and induces growth arrest, but also downregulates mitosis-related genes and upregulates the level of p-ERK1/2. When combined with MEK inhibitors, Molibresib besylate shows a significant synergistic effect, reduces tumor burden in mouse models of leukemia, modulates the immune microenvironment and prolongs survival. Molibresib besylate is widely applicable to research related to acute myeloid leukemia, multiple myeloma, triple-negative breast cancer, small-cell lung cancer and various advanced refractory solid tumors[1][2][3].

    IC50 & Target

    IC50: 32.5-42.5 nM (BET)[1]
    体外実験

    Molibresib (besylate) (10-500 nM; 7 days, single agent; 0.05-1.5 μM; 7 days, in combination with trametinib) alone inhibits primary NrasG12D/+;Asxl1-/- AML cell proliferation in vitro, and in combination with trametinib exerts synergistic anti-proliferative effects on these cells[1].
    Molibresib (besylate) (500 nM; 24-96 h) down-regulates MYC signatures and transiently down-regulates mitotic genes in RKO colorectal cancer cells, and combined treatment with trametinib results in sustained, robust down-regulation of mitotic, E2F, and apoptotic signatures that is greater than either single agent[2].
    Molibresib (besylate) (500 nM; 1-6 days) induces transient G1 arrest in RKO colorectal cancer cells and modest G1 arrest in BxPC-3 pancreatic cancer cells, and combined treatment with trametinib results in sustained G1 arrest in RKO cells and cell death in BxPC-3 cells[2].
    Molibresib (besylate) (100 nM to 1 μM; 1-6 days) up-regulates p-ERK1/2 levels in RPMI-8226 multiple myeloma, NCI-H510 small cell lung carcinoma, and NCI-H526 small cell lung carcinoma cells, and this up-regulation is reversed by co-treatment with MEK inhibitors[2].
    Molibresib (besylate) (500 nM (RPMI-8226), 1 μM (NCI-H510); 96 h) up-regulates ERK activation-associated genes in RPMI-8226 multiple myeloma and NCI-H510 small cell lung carcinoma cells, and this up-regulation is reversed by co-treatment with MEK inhibitors[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Molibresib besylate 関連抗体

    Cell Cycle Analysis[2]

    Cell Line: RKO (BRAFmut, NF1mut CRC) cells, BxPC-3 (KRASmut pancreatic cancer) cells
    Concentration: 500 nM
    Incubation Time: 1 day (cell cycle analysis); 6 days (cell cycle analysis)
    Result: Induced substantial G1 arrest in RKO cells at 1 day, which diminished by 6 days.
    Induced modest G1 arrest in BxPC-3 cells at 6 days.
    Resulted in sustained G1 arrest in RKO cells (with a greater proportion of cells in G1 at 6 days than at 1 day) when combined with trametinib.
    Caused substantial sub-G1 accumulation (indicative of cell death) in BxPC-3 cells at 6 days when combined with trametinib.

    Western Blot Analysis[2]

    Cell Line: RPMI-8226 (KRASmut MM) cells, NCI-H510 (NF1mut SCLC) cells, NCI-H526 (SCLC) cells
    Concentration: 250 nM, 500 nM, 1 μM (RPMI-8226); 100 nM, 1 μM (NCI-H510); 500 nM, 100 nM, 1 μM (NCI-H526)
    Incubation Time: 4 days (RPMI-8226); 3 days (NCI-H510); 1 day, 6 days, 3 days (NCI-H526)
    Result: Increased p-ERK1/2 levels in RPMI-8226 cells after 4 days of single-agent treatment.
    Increased p-ERK1/2 levels in NCI-H510 cells after 3 days of single-agent treatment.
    Increased p-ERK1/2 levels in NCI-H526 cells after 1 and 6 days of single-agent treatment.
    Reversed the Molibresib (besylate)-induced up-regulation of p-ERK1/2 when co-treated with MEK inhibitors (trametinib in RPMI-8226; PD0325901 in NCI-H510 and NCI-H526).

    Real Time qPCR[2]

    Cell Line: RPMI-8226 (KRASmut MM) cells, NCI-H510 (NF1mut SCLC) cells
    Concentration: 500 nM (RPMI-8226); 1 μM (NCI-H510)
    Incubation Time: 96 h
    Result: Up-regulated ERK activation-associated genes (DUSP4, DUSP6, SPRED1, SPRED2, EGR1, ETV5, SPRY4, SPRY2) in RPMI-8226 cells with single-agent treatment.
    Up-regulated ERK activation-associated genes (DUSP4, DUSP6, SPRED1, SPRED2, EGR1, ETV5, SPRY4, SPRY2) in NCI-H510 cells with single-agent treatment.
    Down-regulated ERK activation-associated genes compared to Molibresib (besylate) monotherapy when co-treated with MEK inhibitors (trametinib in RPMI-8226; PD0325901 in NCI-H510).
    体内実験

    Combination of Molibresib besylate and Trametinib (HY-10999) reduces leukemia burden, reverses the immunosuppressive microenvironment, enhances the cytotoxicity of CD8+ T cells, and significantly prolongs survival in a mouse model of NrasG12D/+;Asxl1-/- acute myeloid leukemia[1].
    Combination therapy with Molibresib besylate and Trametinib significantly prolongs survival in a human CMML xenograft mouse model harboring concurrent RAS and ASXL1 mutations[1].
    Combination treatment with Molibresib besylate (15 mg/kg; p.o.; once daily) and Trametinib (1 mg/kg; p.o.; once daily) delays tumor growth in female NCr nu/nu mice inoculated with RKO colorectal cancer xenografts and MDA-MB-231 triple-negative breast cancer xenografts, respectively, and the combined effect is stronger than that of Molibresib besylate alone[2].
    Combination treatment with Molibresib besylate (25 mg/kg; p.o.; once daily) and Trametinib (1 mg/kg; p.o.; once daily) delays tumor growth in female CB.17 SCID mice inoculated with RPMI-8226 multiple myeloma xenografts, and the combined effect is stronger than that of Molibresib besylate alone[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: NCr nu/nu mice with Colorectal cancer (female, 10 or 11 weeks old, implanted with RKO cells for xenograft modeling)[2]
    Dosage: 15 mg/kg (in combination with trametinib 1 mg/kg)
    Administration: p.o.; once daily
    Result: Produced significantly greater tumor growth delay, with statistically significant difference in time to tumor endpoint.
    Animal Model: NCr nu/nu mice with Triple-negative breast cancer (female, 10 or 11 weeks old, implanted with MDA-MB-231 cells for xenograft modeling)[2]
    Dosage: 15 mg/kg (in combination with trametinib 1 mg/kg)
    Administration: p.o.; once daily
    Result: Produced significantly greater tumor growth delay, with statistically significant difference in time to tumor endpoint.
    Animal Model: CB.17 SCID mice with Multiple myeloma (female, 12 weeks old, implanted with RPMI-8226 cells for xenograft modeling)[2]
    Dosage: 25 mg/kg (in combination with trametinib 0.1 mg/kg)
    Administration: p.o.; once daily
    Result: Produced significantly greater tumor growth delay, with statistically significant difference in time to tumor endpoint.
    分子量

    582.07

    分子式

    C28H28ClN5O5S
    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    ClC1=CC=C(C2=N[C@@H](CC(NCC)=O)C3=NN=C(C)N3C4=CC=C(OC)C=C24)C=C1.O=S(C5=CC=CC=C5)(O)=O
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件

    4°C, sealed storage, away from moisture

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
    溶剤 & 溶解度
    体外: 

    DMSO : 25 mg/mL (42.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7180 mL 8.5900 mL 17.1801 mL
    5 mM 0.3436 mL 1.7180 mL 3.4360 mL
    10 mM 0.1718 mL 0.8590 mL 1.7180 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.67 mg/mL (4.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.67 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (26.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.67 mg/mL (4.59 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.67 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (26.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7180 mL 8.5900 mL 17.1801 mL 42.9502 mL
    5 mM 0.3436 mL 1.7180 mL 3.4360 mL 8.5900 mL
    10 mM 0.1718 mL 0.8590 mL 1.7180 mL 4.2950 mL
    15 mM 0.1145 mL 0.5727 mL 1.1453 mL 2.8633 mL
    20 mM 0.0859 mL 0.4295 mL 0.8590 mL 2.1475 mL
    25 mM 0.0687 mL 0.3436 mL 0.6872 mL 1.7180 mL
    30 mM 0.0573 mL 0.2863 mL 0.5727 mL 1.4317 mL
    40 mM 0.0430 mL 0.2148 mL 0.4295 mL 1.0738 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Molibresib besylate Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Molibresib besylate1895049-20-3GSK 525762C I-BET 762 besylateEpigenetic Reader DomainERKExtracellular signal regulated kinaseschronic myelomonocytic leukemiaBRDTBRD3BRD4colorectal cancerBRD2MYCtriple-negative breast canceracetylated histonesacute myeloid leukemiaInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Molibresib besylate
    製品番号:
    HY-13032B
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.